Chloroquine
- Generic Name
- Chloroquine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
- Conditions
- COVID19Acute Respiratory IllnessesCoronavirus
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 4652
- Registration Number
- NCT04303507
- Locations
- 🇰🇪
Mbagathi County Hospital, Nairobi, Kenya
🇲🇱Hospital Of Mali, Bamako, Mali
🇵🇰The Aga Khan University Hospital, Karachi, Pakistan
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
- Conditions
- MalariaVivax MalariaFalciparum MalariaMalaria Recrudescence
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Research Institute for Tropical Medicine, Philippines
- Target Recruit Count
- 159
- Registration Number
- NCT04222088
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ Challenge
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2022-07-12
- Target Recruit Count
- 252
- Registration Number
- NCT03952650
- Locations
- 🇲🇱
Malaria Vaccine Center STTB/MRTC, Bamako, Mali
Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine
- Conditions
- Chloroquine RetinopathyProliferative Nephritis
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT03687905
- Locations
- 🇪🇬
Fatma Gheet, Tanta, Egypt
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
- Conditions
- Vivax MalariaG6PD Deficiency
- Interventions
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Target Recruit Count
- 106
- Registration Number
- NCT03529396
- Locations
- 🇧🇷
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil
🇧🇷Centro de Pesquisa em Medicina Tropical (Cepem), Porto Velho, RO, Brazil
Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria
- Conditions
- Malaria
- Interventions
- Other: Normal SalineBiological: PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 345
- Registration Number
- NCT03503058
- Locations
- 🇮🇩
Department of Internal Medicine, Universitas Indonesia, Jakarta, Indonesia
🇮🇩Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta, Indonesia
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT03449758
- Locations
- 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷Investigational Site Number 250006, Besancon, France
🇫🇷Investigational Site Number 250016, Bordeaux, France
Assessing a Risk Model for G6PD Deficiency
- Conditions
- Malaria, VivaxG6PD Deficiency
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- PATH
- Target Recruit Count
- 54
- Registration Number
- NCT03337152
- Locations
- 🇹🇭
Shoklo Malaria Research Unit (SMRU), Mae Sot, Thailand
Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Registration Number
- NCT03278808
- Locations
- 🇺🇸
WRAIR, Silver Spring, Maryland, United States
🇺🇸Clinical Research Unit, Uniformed Services University of Health Sciences, Bethesda, Maryland, United States
Dose Escalation PfSPZ-CVac
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2021-06-01
- Target Recruit Count
- 55
- Registration Number
- NCT03083847
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.